Alcohol Use DisorderPhase 4NCT05028062
Naltrexone in AUD Reward Drinkers
A Phase 4 study testing XR-NTX 380 mg, intramuscular injection and Medical Management in people with Alcohol Use Disorder and Alcoholism, run by University of Pennsylvania at 1 site in United States.
Trial summary
This study is a phase IV, two-arm, randomized, double-blind, placebo-controlled study to assess whether individuals identified as primarily reward drinkers are significantly more likely to reduce heavy drinking if they receive XR-NTX than a matching placebo injection. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Alcohol Use Disorder, Alcoholism
- What is being tested?
- XR-NTX 380 mg, intramuscular injection and Medical Management
- Type of treatment
- Injection or infusion, Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteUnited States
- Study dates
- 7 Mar 2022to Jul 2028
- Phase
- Phase 4
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18-65 years old
- Willing to provide signed, informed consent and commit to completing the study procedures
- Able to read at an 8th grade or higher level
- Current DSM-5 diagnosis of AUD
- Reports consuming 24+ standard drinks (men) or 18+ standard drinks (women) weekly on average over the month prior to consent
- Expresses a desire to reduce or stop drinking and a willingness to receive two injections of study medication over 8 weeks of treatment.
Show all 9Show fewer
- Either a reward drinker [i.e., an individual with a score of 19 or greater on the reward subscale and less than or equal to 18 on the relief subscale of the Inventory of Drinking Situations (IDS)] or a relief drinker (i.e., an individual with a score of 21 or greater on the relief subscale and less than or equal to 18 on the reward subscale of the IDS).
- Has a stable address in the local area; not planning to move; has documents for an ID check
- Women of child-bearing potential (i.e., who have not had a hysterectomy, bilateral oophorectomy, tubal ligation or are less than two years postmenopausal): must be non-lactating and practicing a reliable method of birth control and have a negative urine pregnancy test prior to the initiation of the study procedures. Examples of medically acceptable methods for this protocol include oral contraceptive pills, intrauterine device, injection of Depo-Provera, Norplant, contraceptive patch, contraceptive ring, double-barrier methods (such as condoms and diaphragm/spermicide), male partner sterilization, abstinence (and agreement to continue abstinence or to use an acceptable method of contraception, as listed above, should sexual activity commence).
Who cannot join
- Planned surgery within the timeframe of the study
- A current, clinically significant physical disease or abnormality on the basis of medical history, physical examination, or routine laboratory evaluation that could interfere with study participation or make it hazardous for the subject to do so (e.g., bleeding disorder, pancreatitis, epilepsy, diabetes, liver disease, kidney disease, or cardiomyopathy as determined by history and clinical exam); ALAT or ASAT concentration greater than 3 times the upper limit of normal (ULN), or direct bilirubin above the ULN. (Note-abnormal laboratory tests during screening may be repeated once).
- Chronic or episodic painful conditions that could require opioid medications for pain control
- History of seizure disorder (excluding childhood febrile seizures)
- History of allergy or other serious adverse event due to treatment with XR-NTX
- Current psychotic disorder (bipolar, schizophrenia, major depression with suicidal ideation, or psychotic features) identified by clinical examination or the structured interview that could interfere with study participation or make it hazardous for the subject.
Show all 13Show fewer
- Current DSM-5 diagnosis of any drug use disorder other than alcohol, nicotine, or cannabis or a urine drug screen that is positive for benzodiazepines, opioids, amphetamines, cocaine or barbiturates.
- Current treatment with a psychotropic, anticonvulsant, opioid, anticoagulant or AUD treatment medication (i.e., naltrexone, acamprosate, disulfiram, topiramate, gabapentin, varenicline, or baclofen)
- Receipt of any experimental medication within the past 30 days
- In need of medical detoxification from alcohol
- Subjects cannot have been mandated by court for alcohol or drug abuse treatment or have pending legal proceedings that could result in incarceration within 6 months of enrollment.
- Homicidal or other behavioral disturbance that requires immediate clinical attention
- Judged by the principal investigator or his designee to be an unsuitable candidate for study participation
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
University of Pennsylvania Center for Studies of Addiction
Philadelphia, Pennsylvania, 19104
Timothy S. Pond, M.P.H., 215-746-1959 ext. 241, timpond@pennmedicine.upenn.edu
Rachel Weyl, BS, 215-746-1902, rachel.weyl@Pennmedicine.upenn.edu
About this study
Official title: Testing the Reward-Drinker Hypothesis of Naltrexone Using an Extended-Release Formulation
This study is a phase IV, two-arm, randomized, double-blind, placebo-controlled study to assess whether individuals identified as primarily reward drinkers are significantly more likely to reduce heavy drinking if they receive XR-NTX than a matching placebo injection.
Study subjects will receive monthly injections of long-acting injectable naltrexone 380 mg (4 mL) or matching placebo. All subjects will also receive 4 sessions of Medical Management (MM). Post-treatment follow-up visits will be conducted at 4 weeks after the scheduled completion of treatment.
Read the detailed description
Study eligibility is determined at an initial screening visit, which can be completed in a single day or divided over multiple days. Portions of the screening may occur by telephone or video conference. Participants are asked not to drink before this and at all study visits. At all study visits, study staff will check breath alcohol level using a breathalyzer. If the breath alcohol level is greater than 0.02% (which can result from a single standard drink), participants may not be able to complete the visit.
Screening Visit: The screening visit will determine whether the study is a good fit for participants. It take about three hours to complete.
- Participants will be asked to show legal photo ID and undergo a breathalyzer test to ensure that the breath alcohol level is below 0.02% to complete this visit. A reading test wil be given to evaluate participant's ability to understand the consent form and study assessment questionnaires.
- Once the informed consent is complete a study clinician will complete a medical history and perform a physical examination. Study staff will draw approximately 3 tablespoons of blood for standard laboratory tests. Participants will also be asked to provide a urine sample to conduct a urinalysis, drug screen, and a urine pregnancy test (only for for women of childbearing potential--i.e., who have not had a hysterectomy, bilateral removal of the ovaries, or a tubal ligation or is less than two years postmenopausal). We will not include women who are pregnant, breast-feeding.
- Eligible participants will be required to provide the names and contact information of one or two people (trusted friends or family members) who may serve as additional contacts to assist staff with locating participants for safety or other study-related reasons.
- Participants will be asked to complete 4 assessments of about psychological health and alcohol and drug use history.
First Study Drug Visit (Week 1): Staff will contact participants within 1 week after completing the screening visit to inform eligibility status and schedule the next study visit.
- This visit will take approximately one and one-half hours to complete.
- Participants will be asked to complete a breathalyzer test and study staff will measure weight and vital signs (blood pressure and heart rate).
- Woman of childbearing potential, will be asked to provide a urine sample for a pregnancy test.
- Participants will be asked to complete 11 assessments about psychological health and alcohol and drug use history.
- Staff will instruct participants how to use the interactive voice response (IVR) system via telephone. During the 8 weeks of the study, participants will be asked to call a toll-free phone number each day, between 5:00 and 8:00 p.m. to connect to the system. Access to the system via a touch-tone phone requires a study ID and a password. The system has prompts to answer questions about feelings and use of alcohol on the day of the call and the preceding day. It takes about 5 to 8 minutes to complete the daily interview. The IVR system will provide a reminder if a call has not been completed by 8:15 p.m.
- The first brief counseling session will last about 45 minutes. The study nurse will discuss a treatment goal either to drink less or become completely abstinent. The nurse will also encourage participants to consider ways to reduce or stop drinking, based upon the treatment goal.
- Participants will be assigned to receive an injection of study medication administered by the nurse, which will be either XR-NTX or placebo (an inactive substance). The decision as to which medication received will be random, like a flip of a coin. The XR-NTX or placebo will look the same. Neither participants nor any of the study personnel will know which medication is received. In an emergency, though, the study staff in charge of the study medication can be contacted for that information.
- At each visit, study staff will ask about any side effects or other adverse events.
Biweekly Visits (Weeks 2, 4, and 6): At each biweekly visit:
- The staff will check breath alcohol concentration (Breathalyzer), weight, and vital signs and ask about any side effects or other adverse events that were experienced.
- Participants will asked to complete 6 assessments about psychological health and alcohol and drug use history. These should take about 20 minutes to answer.
- Participants will receive brief counseling from the study clinician, which will last about 20 minutes.
- At week 4, woman of childbearing potential, will have another urine pregnancy test. If the urine permanency test is positive, staff will discontinue the medication and the participant will be referred to an obstetrician for care.
- At week 4 the study nurse will give the second injection of XR-NTX or a placebo (an inactive substance)
- Participants will continue to call and complete the toll-free IVR number nightly.
- Endpoint Visit (Week 8): At this visit:
- The staff will measure breath alcohol concentration (Breathalyzer), weight, and vital signs and asked about any side effects or other adverse events that may have experienced.
- The study staff will ask you to complete 11 assessments about your psychological health and your alcohol and drug use history. These should take about 45 minutes to complete.
- Study staff will draw 1 tablespoonful of blood for lab tests.
- Participants will receive brief counseling from the study clinician, which will last about 20 minutes.
Follow-up Visits (4 weeks after endpoint visit): At the follow-up visit (which will take about one hour), the study staff will:
- Check breath alcohol concentration (Breathalyzer), weight and vital signs.
- Draw 1 tablespoonful of blood for lab tests.
- Participants will be asked to complete 9 assessments about psychological health and alcohol and drug use history.
- Once participants have completed the study, they will have an option to receive a letter to inform them whether they received XR-NTX or placebo medication.
Early Termination Visit
- Participants who choose to withdraw from the study before participation is complete will be asked to return to the research center for a visit to allow staff to administer the end-of-study procedures.
- Conditions
- Alcohol Use Disorder, Alcoholism
- Being tested
- XR-NTX 380 mg, intramuscular injection, Medical Management, Placebo intramuscular injection
- Keywords
- XR-NTX, Naltrexone, Alcohol
- Medical subject headings
- Alcoholism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
XR-NTX 380 mg, intramuscular injectionDrug
Also called Vivitrol naltrexone for extended-release injectable suspension
Two doses of XR-NTX 380 mg, intramuscular injection.
Medical ManagementBehavioural
All subjects will receive 8 weeks of medical management (Pettinati et al. 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.
Placebo intramuscular injectionDrug
Also called Inactive placebo
Two doses of XR-NTX 380 mg, intramuscular injection.
| Study group | Role | What they receive |
|---|---|---|
| XR-NTX 380 mg, intramuscular injection | Active comparator | Subjects will receive an injection of XR-NTX 380 mg (4 mL) repeated once after 4 weeks. Receives: Drug: XR-NTX 380 mg, intramuscular injection; Behavioral: Medical Management |
| Inactive placebo intramuscular injection | Placebo comparator | Subjects will receive a placebo injection repeated once after 4 weeks. Receives: Behavioral: Medical Management; Drug: Placebo intramuscular injection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Frequency of heavy drinking days by medication group (timeline follow back calendar).
The number of Heavy Drinking Days during 8 weeks of treatment in the Naltrexone and placebo groups.
Measured: 8 weeks
Secondary outcomes (1)
Frequency of drinking days, and drinks/drinking day by medication group (timeline follow back calendar).
The number of Drinking Days, drinks/drinking day by medication group during 8 weeks of treatment in the Naltrexone and placebo groups.
Measured: 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Aug 2021
- Study start7 Mar 2022
- Primary completionJul 2027 (estimated)
- Study completionJul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alcohol Use DisorderStudies of the same condition, open and under way.
- More trials run by University of PennsylvaniaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Double-blind, placebo-controlled, parallel-group clinical trial
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Pennsylvania
- Sponsor type
- University, hospital or other
- Collaborators
- Alkermes, Inc.
- Responsible party
- Sponsor
- Investigators
- Henry R Kranzler, MD, Principal investigator, University of Pennsylvania
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05028062
- Sponsor's protocol ID
- 849558
- Status last verified
- Jan 2026
- First submitted
- 25 Aug 2021
- Last updated
- 20 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Testing the Reward-Drinker Hypothesis of Naltrexone Using an Extended-Release Formulation
- ClinicalTrials.gov ID
- NCT05028062
- Acronym / sponsor ID
- 849558
- Conditions
- Alcohol Use Disorder, Alcoholism
- Keywords
- XR-NTX, Naltrexone, Alcohol
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- University of PennsylvaniaUniversity, hospital or other
- Collaborators
- Alkermes, Inc.
- Study start
- 7 Mar 2022 (actual)
- Primary completion
- Jul 2027 (estimated)
- Study completion
- Jul 2028 (estimated)
- First posted
- 31 Aug 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a phase IV, two-arm, randomized, double-blind, placebo-controlled study to assess whether individuals identified as primarily reward drinkers are significantly more likely to reduce heavy drinking if they receive XR-NTX than a matching placebo injection.
Study subjects will receive monthly injections of long-acting injectable naltrexone 380 mg (4 mL) or matching placebo. All subjects will also receive 4 sessions of Medical Management (MM). Post-treatment follow-up visits will be conducted at 4 weeks after the scheduled completion of treatment.
Detailed description
Study eligibility is determined at an initial screening visit, which can be completed in a single day or divided over multiple days. Portions of the screening may occur by telephone or video conference. Participants are asked not to drink before this and at all study visits. At all study visits, study staff will check breath alcohol level using a breathalyzer. If the breath alcohol level is greater than 0.02% (which can result from a single standard drink), participants may not be able to complete the visit.
Screening Visit: The screening visit will determine whether the study is a good fit for participants. It take about three hours to complete.
- Participants will be asked to show legal photo ID and undergo a breathalyzer test to ensure that the breath alcohol level is below 0.02% to complete this visit. A reading test wil be given to evaluate participant's ability to understand the consent form and study assessment questionnaires.
- Once the informed consent is complete a study clinician will complete a medical history and perform a physical examination. Study staff will draw approximately 3 tablespoons of blood for standard laboratory tests. Participants will also be asked to provide a urine sample to conduct a urinalysis, drug screen, and a urine pregnancy test (only for for women of childbearing potential--i.e., who have not had a hysterectomy, bilateral removal of the ovaries, or a tubal ligation or is less than two years postmenopausal). We will not include women who are pregnant, breast-feeding.
- Eligible participants will be required to provide the names and contact information of one or two people (trusted friends or family members) who may serve as additional contacts to assist staff with locating participants for safety or other study-related reasons.
- Participants will be asked to complete 4 assessments of about psychological health and alcohol and drug use history.
First Study Drug Visit (Week 1): Staff will contact participants within 1 week after completing the screening visit to inform eligibility status and schedule the next study visit.
- This visit will take approximately one and one-half hours to complete.
- Participants will be asked to complete a breathalyzer test and study staff will measure weight and vital signs (blood pressure and heart rate).
- Woman of childbearing potential, will be asked to provide a urine sample for a pregnancy test.
- Participants will be asked to complete 11 assessments about psychological health and alcohol and drug use history.
- Staff will instruct participants how to use the interactive voice response (IVR) system via telephone. During the 8 weeks of the study, participants will be asked to call a toll-free phone number each day, between 5:00 and 8:00 p.m. to connect to the system. Access to the system via a touch-tone phone requires a study ID and a password. The system has prompts to answer questions about feelings and use of alcohol on the day of the call and the preceding day. It takes about 5 to 8 minutes to complete the daily interview. The IVR system will provide a reminder if a call has not been completed by 8:15 p.m.
- The first brief counseling session will last about 45 minutes. The study nurse will discuss a treatment goal either to drink less or become completely abstinent. The nurse will also encourage participants to consider ways to reduce or stop drinking, based upon the treatment goal.
- Participants will be assigned to receive an injection of study medication administered by the nurse, which will be either XR-NTX or placebo (an inactive substance). The decision as to which medication received will be random, like a flip of a coin. The XR-NTX or placebo will look the same. Neither participants nor any of the study personnel will know which medication is received. In an emergency, though, the study staff in charge of the study medication can be contacted for that information.
- At each visit, study staff will ask about any side effects or other adverse events.
Biweekly Visits (Weeks 2, 4, and 6): At each biweekly visit:
- The staff will check breath alcohol concentration (Breathalyzer), weight, and vital signs and ask about any side effects or other adverse events that were experienced.
- Participants will asked to complete 6 assessments about psychological health and alcohol and drug use history. These should take about 20 minutes to answer.
- Participants will receive brief counseling from the study clinician, which will last about 20 minutes.
- At week 4, woman of childbearing potential, will have another urine pregnancy test. If the urine permanency test is positive, staff will discontinue the medication and the participant will be referred to an obstetrician for care.
- At week 4 the study nurse will give the second injection of XR-NTX or a placebo (an inactive substance)
- Participants will continue to call and complete the toll-free IVR number nightly.
- Endpoint Visit (Week 8): At this visit:
- The staff will measure breath alcohol concentration (Breathalyzer), weight, and vital signs and asked about any side effects or other adverse events that may have experienced.
- The study staff will ask you to complete 11 assessments about your psychological health and your alcohol and drug use history. These should take about 45 minutes to complete.
- Study staff will draw 1 tablespoonful of blood for lab tests.
- Participants will receive brief counseling from the study clinician, which will last about 20 minutes.
Follow-up Visits (4 weeks after endpoint visit): At the follow-up visit (which will take about one hour), the study staff will:
- Check breath alcohol concentration (Breathalyzer), weight and vital signs.
- Draw 1 tablespoonful of blood for lab tests.
- Participants will be asked to complete 9 assessments about psychological health and alcohol and drug use history.
- Once participants have completed the study, they will have an option to receive a letter to inform them whether they received XR-NTX or placebo medication.
Early Termination Visit
- Participants who choose to withdraw from the study before participation is complete will be asked to return to the research center for a visit to allow staff to administer the end-of-study procedures.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Double-blind, placebo-controlled, parallel-group clinical trial
| Arm | Type | Receives |
|---|---|---|
| XR-NTX 380 mg, intramuscular injection | Active comparator | Drug: XR-NTX 380 mg, intramuscular injection, Behavioral: Medical ManagementSubjects will receive an injection of XR-NTX 380 mg (4 mL) repeated once after 4 weeks. |
| Inactive placebo intramuscular injection | Placebo comparator | Behavioral: Medical Management, Drug: Placebo intramuscular injectionSubjects will receive a placebo injection repeated once after 4 weeks. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Age 18-65 years old
- Willing to provide signed, informed consent and commit to completing the study procedures
- Able to read at an 8th grade or higher level
- Current DSM-5 diagnosis of AUD
- Reports consuming 24+ standard drinks (men) or 18+ standard drinks (women) weekly on average over the month prior to consent
Key exclusion criteria (13 listed)
- Planned surgery within the timeframe of the study
- A current, clinically significant physical disease or abnormality on the basis of medical history, physical examination, or routine laboratory evaluation that could interfere with study participation or make it hazardous for the subject to do so (e.g., bleeding disorder, pancreatitis, epilepsy, diabetes, liver disease, kidney disease, or cardiomyopathy as determined by history and clinical exam); ALAT or ASAT concentration greater than 3 times the upper limit of normal (ULN), or direct bilirubin above the ULN. (Note-abnormal laboratory tests during screening may be repeated once).
- Chronic or episodic painful conditions that could require opioid medications for pain control
- History of seizure disorder (excluding childhood febrile seizures)
- History of allergy or other serious adverse event due to treatment with XR-NTX
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| XR-NTX 380 mg, intramuscular injectionAlso: Vivitrol naltrexone for extended-release injectable suspensionTwo doses of XR-NTX 380 mg, intramuscular injection. | Drug | XR-NTX 380 mg, intramuscular injection |
| Medical ManagementAll subjects will receive 8 weeks of medical management (Pettinati et al. 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week. | Behavioural | Inactive placebo intramuscular injection, XR-NTX 380 mg, intramuscular injection |
| Placebo intramuscular injectionAlso: Inactive placeboTwo doses of XR-NTX 380 mg, intramuscular injection. | Drug | Inactive placebo intramuscular injection |
Primary outcome
Frequency of heavy drinking days by medication group (timeline follow back calendar).
Time frame: 8 weeks
The number of Heavy Drinking Days during 8 weeks of treatment in the Naltrexone and placebo groups.
1 secondary outcome
Frequency of drinking days, and drinks/drinking day by medication group (timeline follow back calendar).
Time frame: 8 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jan 2026.
Related trials for Alcohol Use Disorder
Recruiting
Tdcs And cogNitive traininG cOmbined for AUD (TANGO)
Alcohol Use Disorder, Addiction
Not yet recruitingPhase 1/2
Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients
Alcohol Withdrawal, Alcohol Abstinence
Not yet recruiting
PNF RCT to Decrease Alcohol Use and Increase HIV Prevention
HIV (Human Immunodeficiency Virus), Alcohol Misuse
RecruitingObservational study
SMART-r: Substance Monitoring and Active Relapse Tracking Repository
Alcoholism, Substance-Related Disorders
RecruitingPhase 2
Phase 2 Study of Apremilast in Women and Men With Alcohol Use Disorder
Alcohol Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Henry R Kranzler, MD principal investigator
University of Pennsylvania
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing XR-NTX 380 mg, intramuscular injection and Medical Management in people with Alcohol Use Disorder and Alcoholism, run by University of Pennsylvania at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Timothy S Pond, MPH (215-746-1959, timpond@pennmedicine.upenn.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Frequency of heavy drinking days by medication group (timeline follow back calendar). (time frame: 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2026.